Medical Condition

prostate cancer

Total Trials

103

Recruiting Now

103

Trial Phases

Phase 4, Phase 1, Phase 2

Prostate cancer trials now span the full disease spectrum from localized low-risk disease (active surveillance vs. focal therapy) to metastatic castration-resistant prostate cancer (mCRPC), where novel AR pathway inhibitors, PARP inhibitors for BRCA-mutated tumors, and radioligand therapies (PSMA-lutetium) have changed the treatment landscape.

Current trials evaluate darolutamide combinations, PSMA-directed radioligand therapy (177Lu-PSMA-617) in earlier disease settings, bispecific antibodies targeting PSMA and CD3, and CRISPR-based gene editing approaches. PSA decline, rPFS, and overall survival remain primary endpoints, with ctDNA and PSMA-PET emerging as early response biomarkers.

Frequently Asked Questions — prostate cancer Clinical Trials

How many clinical trials are currently recruiting for prostate cancer?

ClinicalMetric currently tracks 103 actively recruiting clinical trials for prostate cancer, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 103. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for prostate cancer?

prostate cancer research spans Phase 1 (16 trials), Phase 2 (27 trials), Phase 3 (5 trials), Phase 4 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a prostate cancer clinical trial?

Eligibility criteria for prostate cancer trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Phase 4

Top Sponsors

Memorial Sloan Kettering Cancer Center 3 trials

Peking University First Hospital 2 trials

Astellas Pharma Global Development, Inc. 2 trials

Anhui Provincial Hospital 2 trials

Universitaire Ziekenhuizen KU Leuven 2 trials

prostate cancer

Frequently Asked Questions — prostate cancer Clinical Trials

Recruiting Clinical Trials

Implementation of Precision Medicine in High-risk Prostate Cancer

Preop Laxatives in Robotic Urologic Surgery

The Role of Levator Ani Muscle Reconstruction Technology in Urinary Incontinence Recovery

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer

Video Education With Result Dependent dIsclosure

A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer

Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis

ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials

First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine

Advanced Radiotherapy (ART) in Prostate Cancer (PROST-ART)

Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program

Cost-utility of Focal HIFU vs Prostatectomy

Feasibility Trial of Single-Dose Radiotherapy for Localized Low and Intermediate Risk Prostate Cancer

Prostate Cancer Genetic Risk Evaluation and Screening Study

Head-to-head Comparison of [18F]F-PSMA-N5 With [18F]F-PSMA-1007 PET/CT in PCa Diagnosis, Recurrence, and Metastasis

The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia

Pathological Positivity Rate in Prostate Cancer Patients with PI-RADS 4 and First Negative Biopsy

MRI-targeted Biopsy of the Prostate: Software Versus Visual Registration in the Accuracy of Prostate Cancer Detection

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Detecting Clinically Significant Prostate Cancer With Advanced MRI Protocols and Extensive Histopathology

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

The Effect of Multidisciplinary Care Approach on CV Risk Modification in CaP Patients Receiving ADT

National Robotics-Assisted Radical Prostatectomy Database

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer

Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients

The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)

Prospective Database of Clinical Outcomes Following Cryotherapy for Ablation of Clinically Localized Prostate Cancer

Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

All-in-One Prostate Cancer Staging with MRI

A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin

Effectiveness of Focal Therapy in Men With Prostate Cancer

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

Prostate Cancer IRE Study (PRIS)

Streamlined Geriatric and Oncological Evaluation Based On IC Technology

Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft

Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE)

Chronic Radiation Induced Bowel Toxicity Study

A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Diffusion Basis Spectrum Imaging of the Prostate

Micro-UltraSound In Cancer - Active Surveillance

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer

Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

Long-term Better Than Short-term ADT With Salvage RT

ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium

68Ga-PSMA PET/MRI in Conjunction With mpMRI for Evaluating Prospective Prostate Cancer Risk

ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0

NLP-Based Feedback to Improve Risk Comms and Informed Shared Decision Making

Carbon Ion Followed by Proton Radiotherapy for Prostate Cancer With Pelvic Lymph Nodes Metastases

Improving Health Literacy in African-American Prostate Cancer Patients

Transperineal Laser Ablation Treatment (TPLA) for Prostate Cancer (PCa) Registry

Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer

Dutch National Randomized Study: PSMA-PET/CT As a Triage Tool for Pelvic Lymph Node Dissection in Prostatectomy Patients

Focal or Radical Therapy: a Lesion-based Molecular Evaluation in Prostate Cancer

Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

PRISM: Patient Experiences With PET Imaging in Prostate Cancer

TherApeutics in Early ProState Cancer (TAPS02)

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer